Legemidler

Eksperter: (Klikk på et navn for nærmere beskrivelse)


Phone: +4777646169
Research areas:

Permeabilitet over biologiske barrierer. (Snurr film under for mer informasjon)

 

The phospholipid vesicle-based permeation assay (PVPA)

Liposomer som legemiddelbærer

Liposomer som modellsystem for celler og bakterier i interaksjonsstudier

Delivery av lipofile virkestoff

 


Publikasjonsliste

Cand.Pharm. avhandling
Incorporation of Camptothecin in liposomes, metod development and incorporation efficacy screening using different liposome formulations (June 2003)

PhD avhandling
The Phospholipid Vesicle-Based Barrier: A Novel Method for Passive Drug Permeability Screening (June 2007)

 

Populærvitenskapelige publikasjoner online

Forskningspodcast fra UiT Norges arktiske universitet (2018)

Hvordan velge de beste kandidatene for fremtidens legemidler? (2018)

42 millioner kroner for utvikling av persontilpasset medisin (2018)

Så lenge holder solkremen din (2017)

Er det sant at man må kaste solkremen etter ett år? (2016)

Skammelig nedprioritering (2016)

Er kvinnesykdommer mindre viktige? (2016)

Skammelig nedprioritering av forskning på kvinnesykdommer (2016)

Finner de beste legemidlene- uten dyreforsøk (2015)

How long before it hits (2014)

Gjennombrudd: Dyreforsøk med brannskader kan erstattes (2014)

Hermer stoffopptak via hud og tarm (2012)

Legemidler og barrierer (2012)

 

Publikasjoner i internasjonale peer-reviewed journaler

36) M. Falavigna, M. Klitgaard, E. Steene and G. E. Flaten (2019) Mimicking regional and fasted/fed state conditions in the intestine with the mucus-PVPA in vitro model: the impact of pH and simulated intestinal fluids on drug permeability, European Journal of Pharmaceutical Sciences, accepted
35) S. Ternullo, P. Basnet, A. M. Holsæter, G. E. Flaten, L. de Weerd, N. Škalko-Basnet (2018) 
Deformable liposomes for skin therapy with human epidermal growth factor: The effect of liposomal surface charge. European Journal of Pharmaceutical Sciences, in press, doi:10.1016/j.ejps.2018.10.005
34) P. Berben, A. Bauer-Brandl, M. Brandl, B. Faller, G. E. Flaten, A. Jacobsen, J. Brouwers and P. Augustijns (2018)
Drug Permeability Profiling using Cell-Free Permeation Tools: An Overview and Their Applications, EurJPharmSci, 119, p 219-233 (open access)
33) M. Falavigna, M. Klitgaard, C.  Brase, S.  Ternullo, N. Škalko-Basnet, G. E. Flaten (2018)
Mucus-PVPA (Mucus Phospholipid Vesicle-based Permeation Assay): an artificial permeability tool for drug screening and formulation development, Int J Pharm, DOI: 10.1016/j.ijpharm.2017.12.038
32) S. Ternullo, L. de Weerd, A. M. Holsæter, G. E. Flaten, N. Škalko-Basnet (2017)
Going skin deep: a direct comparison of penetration potential of lipid-based nanovesicles on the isolated perfused human skin flap model, European Journal of Pharmaceutics and Biopharmaceutics, 121, 14-23
30) J. Kumari, G. E. Flaten, N. Škalko-Basnet and H. Tveiten (2017) 
Molecular transfer to Atlantic salmon ovulated eggs using liposomes, Aquaculture, 479, 404–411
29) T. Andersen, E. Mishchenko, G. E. Flaten, J. Sollid, S. Mattsson, I. Tho and N. Skalko-Basnet (2017)
Chitosan-based nanomedicine to fight genital Candida infections: Chitosomes, Marine Drugs, 15, 64, doi:10.3390/md15030064
28) S. Ternullo, L. de Weerd, G. E. Flaten, A. M. Holsæter and N. Skalko-Basnet (2017)
The isolated perfused human skin flap model: A missing link in skin penetration studies? European Journal of Pharmaceutical Sciences,  96(1), 334-341
27) A. Engesland, N. Škalko-Basnet, G. E. Flaten (2016)
In vitro models to estimate drug penetration through the compromised stratum corneum barrier, Drug Development and Industrial Pharmacy, 421751, http://www.tandfonline.com/doi/full/10.3109/03639045.2016.1171334
26) E. Naderkhani, T. Vasskog, G.E. Flaten (2015)Biomimetic PVPA in vitro model for estimation of the intestinal drug permeability using fasted and fed state simulated intestinal fluids, European Journal of Pharmaceutical Sciences, 73, 64-7
25) G.E Flaten, Z. Palac, A.Engesland, J. Filipović-Grčić, Ž. Vanić and N. Škalko-Basnet (2015) In vitro skin models as a tool in optimization of drug formulation, European Journal ofPharmaceutical Sciences, 75, 10–24
24) T. Andersen, S. Bleher, G.E. Flaten, I. Tho, S. Mattsson, N. Skalko-Basnet (2015) Chitosan in mucoadhesive drug delivery: Local vaginal therapy, Marine Drugs,13, 222-236
23) A. Engesland, N. Škalko-Basnet, G.E. Flaten (2015) PVPA and EpiSkin® in Assessment of Drug Therapies Destined for Skin Administration, Journal of Pharmaceutical Sciences, 104, 1119-1127
22) S.Fulsundar, K. Harms, G.E. Flaten, P. Johnsen, B. Chopade, and K. Nielsen (2014) Gene transfer potential of outer membrane vesicles of Acinetobacter baylyi and effects of stress on vesiculation, Applied and Environmental Microbiology, 80(11), 3469–3483 
21) E. Naderkhani , J. Isaksson, A. Ryzakov, G.E. Flaten (2014) Development of a biomimetic phospholipid vesicle-based permeation assay (PVPA) for the estimation of intestinal drug permeability, Journal of Pharmaceutical Sciences, 103:1882–1890
20) Z. Palac, A. Engesland, G.E. Flaten, N. Škalko-Basnet, J. Filipović-Grčić, Ž. Vanić (2014) Liposomes for (trans)dermal drug delivery: the skin-PVPA as a novel in vitro stratum corneum model in formulation development, Journal of Liposome Research,  24(4): 313–322
19)  E. Naderkhani,  A. Erber, N. Škalko-Basnet, G.E. Flaten (2014) Improved permeability of acyclovir: Optimization of mucoadhesive liposomes using the PVPA model,  Journal of Pharmaceutical Sciences, 103, 661-668
18) T. Andersen, Ž. Vanić, GE Flaten, S. Mattsson, I. Tho, N. Škalko-Basnet (2013) Pectosomes and chitosomes as delivery systems for metronidazole: The one-pot preparation method, Pharmaceutics, special issue on Liposome Technology, 5: 445-456 
17) Whitaker, RD.; Ingebrigsten, SG; Naderkhani, E; Skar, M L; Flaten, GE (2013) Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin, Journal of Liposome Research, 23(4), 298-310
16) Engesland, A.; Skar, M.; Hansen, T.; Skalko-Basnet, N.; Flaten, G. E. (2013) New Applications of PVPA: Permeation Model Mimicking Skin Barrier, Journal of Pharmaceutical Sciences, 102:1588-1600
15) Flaten, G. E.; Chang, T. T.; Phillips, W; Brandl, M.; Bao, A. and Goins, B Liposomal Formulations of Poorly Soluble Camptothecin -Drug Retention and Biodistribution, Journal of Liposome Research (2013),  23(1), 70-81
14) V. Tørfoss, J. Isaksson, D, Ausbacher, B.O. Brandsdal, G. E. Flaten, T. Anderssen,  C. de A. Cavalcanti-Jacobsen, M. Havelkova, L. T. Nguyen,  H. J. Vogel,M. B. Strøm Improved anticancer potency by head-to-tail cyclisation of short cationic anticancer peptides containing a lipophilic ß2,2-amino acid, Journal of Peptide Science (2012), 18(10), 609-619
13) J. Isaksson, B.O. Brandsdal, M. Engqvist, G. E. Flaten, J .S. Svendsen and W. Stensen A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption, J Med Chem (2011) 54, 5786-5795
12) S.M. Fischer, G. E. Flaten, E. Hagesæther, G. Fricker, M. Brandl In Vitro Permeability of Poorly Water Soluble Drugs in the Phospholipid Vesicle-Based Permeation Assay (PVPA): The Influence of Non-Ionic Surfactants,  J Pharm Pharmacol 2011, 63, 1022-1030
11) G.E. Flaten, K. Gabor, W. Stensen, G. Isaksen, R. Karstad, J.S. Svendsen, H. Daniel, and J.Svenson In vitro characterisation of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides, J Med Chem 2011 54(7), 2422-2432
10) T.Hansen, D.Ausbacher, G. E. Flaten, M. Havelkova, and M. B. Strøm Synthesis of cationic antimicrobial β2,2-amino acid derivatives with potential for oral administration, J Med Chem 2011 , 54 (3), 858–868
9) J.Kanzer, I. Tho, G.E. Flaten, M. Maegerlein, P. Hoelig, G. Fricker, M. Brandl In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid veicle-based barrier, Journal of Pharmacy and Pharmacology,2010, 62: 1591–1598
8) J. Svenson,  R. Karstad, G. E. Flaten, B. Brandsdal, M. Brandl, J. S. Svendsen Altered activity and physico-chemical properties of short cationic antimicrobial peptides by incorporation of arginine analogs, Mol. Pharm, vol 6, no 3, 996-1005 (2009)
7) G. E. Flaten, O. Awoyemi, K. Luthman, M. Brandl, U. Massing The phospholipid vesicle-based permeability assay: 5. Development towards an automated procedure for high throughput permeability screening, JALA, 14, 12-21 (2009)
6) M. Brandl, G.E. Flaten and A. Bauer-Brandl Passive Diffusion Across Membranes in Hoboke (ed) Wiley Encyclopedia of Chemical Biology, John Wiley and Sons, 3, 541-550 (2009) 
5) G. E. Flaten, K. Luthman, T. Vasskog, M. Brandl  Drug permeability across a phospholipid vesicle-based barrier: 4. The effect of tensides, co-solvent and pH changes on barrier integrity and on drug permeability, Eur. J. Pharm. Sci. 34, 173-180 (2008)
4) G.E Flaten, M.L. Skar, K. Luthman, M. Brandl Drug permeability across a phospholipid vesicle-based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on barrier integrity and on the permeability, Eur. J. Pharm. Sci. 30, 324-332 (2007)
3) G. E. Flaten, H. Bunjes, K. Luthman, M. Brandl Drug permeability across a phospholipids vesicle-based barrier: 2. Characterization of barrier structure, storage stability and stability towards pH changes, Eur. J. Pharm. Sci. 28, 336-343 (2006).
2) G. E. Flaten, A.B. Dhanikula, K. Luthman, M.Brandl Drug permeability across a phospholipid vesicle barrier: a novel approach for studying passive diffusion, Eur. J. Pharm. Sci. 27, 80-90 (2006).
1) A.M. Sætern, G.E. Flaten, M. Brandl A method to determine the incorporation capacity of Camptothecin in liposomes AAPS PharmSciTech 5 (3) article 40 (2004)
 

 


Phone: +4777646719
Research areas:

Mine forskningsinteresser samsvarer med forskningsinteressene til gruppa "Drug transport and delivery".

og angår formulering og optimalisering av legemiddelformuleringer for topical- (sårbehandling) og systemisk- (injeksjonsmedisin) administrasjo mtp:

  • Holdbarhet/stabilitet
  • Brukervennlighet
  • Effekt
  • Bivirkningsprofil
  • Fremstillingsmetode

Karakterisering av legemiddelformuleringens fysikalskjemiske-, biofarmasøytiske- og kliniske/terapeutiske egenskaper skjer vha a in vitro, ex vivo og in vivo testing.